Company / Shareholders' Equity
Kymera Therapeutics, Inc. Shareholders' Equity History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$1.6B
FY2025
5-year range
-$74.4M / $1.6B
FY2021-FY2025
Trend
+89.0%
vs FY2024
Sector context
#32 of 213
Health Care
What the data says
Kymera Therapeutics, Inc.'s shareholders' equity of $1.6B is higher than 85% of companies in the Health Care sector (FY2025). Shareholders' Equity has fluctuated over the past 7 years, ranging from -$74M in FY2021 to $1.6B in FY2025.
Based on SEC 10-K filings.
$1.6B in FY2025 with a 3-year CAGR of +47.7%. Top quartile in the Health Care sector.
Improved from $395M to $1.6B over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +47.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
-38.0% below sector average
Key checks
Key Insights
- 3-year CAGR of +47.7%, indicating consistent growth.
- In FY2025, shareholders' equity increased 89.0% year-over-year.
- Ranks #32 out of 213 companies in the Health Care sector.
- Lowest shareholders' equity in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score 3.27 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.6B | +89.0% |
| FY2024 | $835.6M | +111.6% |
| FY2023 | $395.0M | -19.4% |
| FY2022 | $490.2M | +758.8% |
| FY2021 | -$74.4M | -116.1% |
| FY2020 | -$34.4M | +53.7% |
| FY2019 | -$74.4M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 30, 2026